This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MURA Mural Oncology (MURA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Mural Oncology Stock (NASDAQ:MURA) Get Mural Oncology alerts:Sign Up Key Stats Today's Range$2.04▼$2.0450-Day Range$2.02▼$2.1052-Week Range$1.53▼$2.98VolumeN/AAverage Volume227,153 shsMarket Capitalization$35.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Mural Oncology, Inc. (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents. Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection. Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development. The company’s interdisciplinary team combines expertise in oncology research, drug development and translational science to address unmet needs across multiple cancer indications.AI Generated. May Contain Errors. Read More Receive MURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mural Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MURA Stock News HeadlinesRecursion names Vicki Goodman as CMOMarch 25, 2026 | msn.comMural Oncology plc: Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | finanznachrichten.deRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 15 at 1:00 AM | Porter & Company (Ad)Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | globenewswire.comMural Oncology Announces Sanction of the Scheme by the High CourtDecember 3, 2025 | globenewswire.comMural Oncology plc: Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyNovember 26, 2025 | finanznachrichten.deMural Oncology announces final cash consideration payable on acquisition closeNovember 26, 2025 | msn.comMural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyNovember 26, 2025 | globenewswire.comSee More Headlines MURA Stock Analysis - Frequently Asked Questions How were Mural Oncology's earnings last quarter? Mural Oncology PLC (NASDAQ:MURA) posted its earnings results on Thursday, November, 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. What other stocks do shareholders of Mural Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mural Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings11/06/2025Today6/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 MURA's financial health is in the Yellow zone, according to TradeSmith. MURA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MURA Previous SymbolNASDAQ:MURA CIK1971543 Webwww.muraloncology.com Phone353-1-905-8020FaxN/AEmployees119Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$128.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-112.17% Return on Assets-89.37% Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book0.25Miscellaneous Outstanding Shares17,344,000Free Float16,962,000Market Cap$35.38 million OptionableOptionable Beta2.93 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MURA) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
